---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-062003"
form_type: "8-K"
ticker: "ERAS"
cik: "0001761918"
company_name: "Erasca, Inc."
filed_at: "2023-11-09T23:59:59+00:00"
generated_at: "2026-06-08T07:14:23.659162+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Erasca Q3 net loss $30.4M ($0.20/shr); cash $343.6M; first patient dosed in SEACRAFT-1

## Summary
- Net loss $30.4M ($0.20/shr) vs $35.5M ($0.29/shr) in Q3 2022; decrease in R&D expenses to $25.2M.
- Cash, equivalents, and marketable securities $343.6M at Sep 30, 2023, down from $435.6M at Dec 31, 2022; runway into H2 2025.
- First patient dosed in SEACRAFT-1 Phase 1b (naporafenib + trametinib) for RAS Q61X solid tumors in Aug 2023.
- Upcoming catalysts: SEACRAFT-1 initial data H2 2024; SEACRAFT-2 Phase 3 start H1 2024; HERKULES-3 expansion data H2 2023-H1 2024.
- THUNDERBBOLT-1 initial Phase 1 monotherapy data in recurrent GBM expected H2 2023.

## SEC filing metadata
- accession: 0000950170-23-062003
- form_type: 8-K
- ticker: ERAS
- cik: 0001761918
- company_name: Erasca, Inc.
- filed_at: 2023-11-09T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1761918/000095017023062003/0000950170-23-062003-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1761918/000095017023062003/eras-20231109.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-062003
- JSON: https://secwatch.observer/filing/0000950170-23-062003.json
- Plain text: https://secwatch.observer/filing/0000950170-23-062003.txt

## Key facts
- Earnings Releases
  Erasca, Inc. reported the quarter ended September 30, 2023 results: net income Net loss was $30.4 million, or $(0.20) per basic and diluted share, EPS $(0.20) per basic and diluted share.
  - Period: the quarter ended September 30, 2023
  - Net income: Net loss was $30.4 million, or $(0.20) per basic and diluted share
  - EPS: $(0.20) per basic and diluted share
  - Result: reported results
  source text: Erasca Reports Third Quarter 2023 Financial Results and Business Updates
  evidence_url: https://www.sec.gov/Archives/edgar/data/1761918/000095017023062003/0000950170-23-062003-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.